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SUMMARY Results of determination of circulating histamine releas-
ing autoantibodies using histamine release urticaria test in 12 children 
(aged 3 to 18 years, mean age 8.5 years; 7 female and 5 male) with 
chronic urticaria are presented. Standard work-up including detailed his-
tory, allergy testing and routine laboratory findings did not disclose any 
plausible cause of chronic/recurrent urticarial eruption in these children. 
All children underwent serum-induced basophil histamine release urti-
caria test. At serum dilution of 12.5%, the mean percent of histamine lib-
eration was 40.8% (range 18%-77%; normal <16.5%), which indicated 
the presence of autoantibodies to FcεRIα and/or to the IgE-FcεRI com-
plex. The percent of histamine release did not correlate with patient age 
or duration and severity of symptoms. Thus the autoimmune basis of 
chronic urticaria was established. Associated antithyroid autoantibodies 
were found in two patients. Complete or partial remission was obtained 
with treatment that included antihistamines, low salicylate-low preserva-
tive diet in all, and high dose intravenous immunoglobulin in 3 children.
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IntRODUCtIOn
Chronic urticaria (CU) is a clinical skin affec-
tion marked by wheals, erythema and itching that 
appear transiently or persist up to 24 hours, and 
recur for 6 weeks or more (1,2). Health-related 
quality of life is significantly influenced by recur-
rence and duration of patient symptoms (3). Der-
mal mast cell degranulation and mediator release 
(histamine and cell-cell signaling molecules) are 
thought to play a central role (4). The precipitating 
stimuli may include pressure, stroking (dermog-
raphism), water immersion (aquagenic urticaria), 
solar ultraviolet radiation, cold exposure, increase 
in central body temperature (fever, physical effort, 
sweating: cholinergic urticaria). Ingested chemical 
substances known to induce mast cell degranula-
tion, e.g., salicylates, preservatives, opiates and 
non-steroidal antiphlogistics, are often implicated 
in the chronicity and flare-ups. Chronic bacterial 
and viral infections (Helicobacter pylori, Yersinia 
enterocolitica, hepatitis B, Epstein-Barr virus and 
possibly chronic focal infections in the ear-nose-
throat region) or collagen vascular diseases can 
produce the clinical condition of chronic urticaria 
(5).  
The term chronic idiopathic urticaria (CIU) has 
been used to describe the set of patients with no 
overt underlying disease. In a significant number 
of these patients (30%-60%, varying by source) 
it has been possible to prove the autoreactive 
nature of CIU by indirect in vivo identification of 
own humoral factors inducing local wheal to intra-
dermally injected autologous serum (autologous 
serum skin test, ASST), or in vitro by measuring 
patient serum induced donor basophil histamine 
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release (Histamine Release-Urticaria test; HR-ur-
ticaria test) (6-8). The latter test detects the pres-
ence of the IgG1 and IgG3 subclass autoantibodies 
directed against the α-subunit of the high-affinity 
IgE receptor (FcεRIα) and/or the IgE antibody it-
self when bound to the FcεRI on the mastocyte 
(9). Besides these autoantibodies, specific differ-
ences in the expression of FcεRI-signaling mole-
cules in the basophils or mast cells of CIU patients 
seem to be emerging as factors in the persistence 
of urticarial eruptions (10).
Chronic autoimmune urticaria seems to be 
as common in children (30% of CIU) as in adults 
(30%-40%) (11). According to current recommen-
dations, the HR-urticaria test should be used to 
confirm positive results of ASST in patients with 
CU (12). The present paper is aimed to present 
the results of determination of circulating hista-
mine releasing autoantibodies using HR-urticaria 
test in 12 children with CU. 
PAtIEntS AnD MEthODS
In the period from September 2003 to February 
2006, 13 children (aged 3 to 18 years, mean age 
8.5 years; 7 female and 5 male) with CIU were 
found to be on the HR-urticaria test. Photograph-
ing (Figs. 1-4) was done before therapy. All study 
children were referred for allergy diagnosis and 
had been under previous dermatologic outpa-
tient surveillance receiving chronic or intermittent 
antihistamine therapy. None was taking steroids 
or immunosuppressive therapy at the time of in-
vestigation. In six patients, no provocative factors 
could be identified (Table 1; Figs. 1 and 2). Anti-
histamine therapy was stopped at least 14 days 
before skin testing or serum sample collection.





(weeks) Initial trigger Trigger
Associated 
disorder
1 A.D., m 56 u, purpuric 7    
2 B.M., f 42 u 11    
3 FN, f 156 u 10 Engerix? 12 days before   
4 J.D., m 156 u, ae 44














6 K.K., f 132 u, ae 12   cerebral AV malformation
7 K.J., m 97 u, 71   
8 M.M., f 172 u 8 ibuprofen,Vegeta, Nutela stroking  
9 O.K., f 110 u, ae 22    
10 P.P., f 82 u, plaques 12 melted cheese, chocolate dessert aquagenic, stroking  
11 Š.S., m 60 em 67  stroking, pressure  
12 B.S., m 103 u 72    
f – female; m – male; u – urticaria; ae – angioedema; a – anaphylaxis; dg – dermographism; em – erythema multiforme;  
CMV – cytomegalovirus
Figure 1. Chronic urticaria manifesting as erythe-
ma multiforme in patient 11.
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Standard work-up included full past medical 
history, physical examination, skin prick test, com-
plete blood count, blood chemistry, C-reactive pro-
tein, antistreptolysin-0-antibodies, immunoglobu-
lins, serum complement components C3 and C4, 
and total and specific IgE. All children underwent 
serum-induced HR-urticaria test. Prick testing in-
cluded a battery of standard inhaled and food al-
lergens as well as preservatives. 
The concentration of total IgE was deter-
mined by the Microparticle Enzyme Immunoas-
say (MEIA) method and reagents (Abbott, USA). 
The analysis is based on the ‘sandwich’ technique 
and antigen-antibody complex labeling (13). The 
method sensitivity is 0.048 IU/L (data from pack-
age insertion). 
The concentration of allergen specific IgE was 
measured by UniCAP method, a ‘second-gen-
eration’ in vitro method (Phadia, Sweden), where 
high sensitivity is achieved by use of a three-di-
mensional cellulose carrier (14). The confidence 
interval is from 0.35 kUA/L (class 1) to 100 kUA/L 
(class 5). Class 0 defaults values up to 0.35 kUA/L, 
and class 6 defaults values over 100 kUA/L. Cali-
brators for determination of total and specific IgE 
were calibrated according to the World Health Or-
ganization Second International Reference Prepa-
ration for Human IgE (WHO 2nd IRP 75/502).
Figure 2. Dermographism in patient 8.
table 2. Diagnostic work-up and treatment
No. HR-test 
(%)
Prick test Total IgE
(kU/L)
Specific IgE (kUA/L) ALT 
(U/L)
Thyroid 
antibody IVIG Therapy Outcome





2 36 0 13  18   cetirizine partly controlled
3 66 0 28.6  17 hTgAb <20 kI/L  loratadine controlled
4 24 0 141.4 Penicilloyl G, Penicilloyl V, Amoxicilloyl: <0.35 9
hTgAb 25.0 
kIU/L (<20)  1 treatment loratadine controlled
5 54 0 7
Dermatophagoides 
pteronyssinus, Penicilloyl 
G, Penicilloyl V, 
Amoxicilloyl: <0.35
14 TPO 10.43 kIU/L (<50) 
ANA negative
 loratadine controlled
6 77 0 110  23
hTgAb 46.7 
kIU/L (<20), 





7 18 0 237  16  recommended loratadine partly controlled






kIU/L, TPO <10 
kIU/L
 fexofenadine controlled
9 22 0 275.4 Dactylis, Ambrosia, Alternaria, feathers: <0.35 11
hTgAb <20 
kIU/L 1 treatment loratadine controlled
10 61 Preservative 3+ 23.2 Dermatophagoides pteronyssinus: 0.50 9  recommended loratadine
partly 
controlled
11 47 Preservative 2+ 50.2 Phadiatop: negative 28   2 treatments loratadine partlycontrolled
12 30 0 45 Penicilloyl G, Penicilloyl V, Amoxicilloyl: <0.35 28   loratadine controlled
ALT – alanine aminotrasferase; IVIG – intravenous immunoglobulin; hTgAb – human anti-thyreoglobulin antibody; CS – corticosteroids; 
TPO – thyroid peroxidase antibody; TSH – thyroid-stimulating hormone; ANA – antinuclear antibodies; specific IgE for standard inhaled 
and food allergens was <0.35 kUA/L (lower limit of confidence) in children No. 1, 2, 6 and 7.
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Serum-induced HR-urticaria test was per-
formed according to the method of Stahl Skov in 
the RefLab, Copenhagen, Denmark (www.reflab.
dk) (15). In brief, 40 μL of patient serum (pre-
sumed to contain antibodies to either FcεRIα or 
IgE- FcεRI complex) diluted 1:2, 1:4 and 1:8 (50%, 
25% and 12.5%) respectively, was incubated with 
healthy donor basophil leukocytes for 60 minutes 
at 37 °C. Released histamine was measured us-
ing the glass fiber method. The histamine released 
was expressed as a percentage of histamine con-
tent. A histamine release >16.5% is considered as 
a positive test result, meaning that patient serum 
contains circulating autoantibodies, predominant-
ly IgG1 and IgG3, specific for the FcεRIα  or IgE-
FcεRI complex. 
RESUltS
All children had negative skin prick test to a 
panel of common inhalant and nutritional allergens 
(Table 2). In two patients there was a moderate 
positivity to preservatives (skin prick test of 2+, i.e. 
average wheal diameter greater than buffer and 
less than histamine reaction). 
Total serum IgE was increased in five children, 
while in the remaining eight children it was below 
the upper reference limit in our population of chil-
dren (16). Specific IgE was <0.35 kUA/L (the lower 
limit of confidence) in nine (75%) children, while 
one child had >0.35 kUA/L (Dermatophagoides 
pteronyssinus 0.50 kUA/L). Seven children had 
thyorid antibodies tested and three were found to 
be positive; of these, only one girl had associated 
hormonal disorder and was receiving hormone 
replacement (Fig. 3). The remaining biochemical 
and hematologic findings were within the refer-
ence range. At serum dilution of 12.5%, the mean 
percent of histamine liberation was 40.8% (range 
18%-77%; normal <16.5%) (Table 2), which indi-
cated the presence of autoantibodies to FcεRIα 
and/or to the IgE-FcεRI complex. The percent of 
histamine release did not correlate with patient 
age or duration and severity of symptoms. 
Children were treated with long-term antihista-
mine therapy and low salicylate-low preservative 
diet according to a written list of potentially offend-
ing natural and commercially available nutrients 
(17). A satisfactory clinical response was evident 
within 3-6 weeks in all but three children. These 
were subsequently treated with high dose intrave-
nous immunoglobulin (1 g/kg in a single infusion 
over 6-12 hours). Long-lasting remission was ob-
tained in two patients, while one girl relapsed 4 
weeks after IVIG, which was then repeated, with 
the same outcome (Fig. 4). Further treatment was 
limited to the diet and antihistamines.
DISCUSSIOn
An autoimmune pathogenesis in 12 pediatric 
patients with CIU was confirmed by the HR-urti-
caria test. Significant histamine liberation from 
basophil granulocytes of healthy donors was in-
duced by the sera of patients, testifying indirectly 
the presence and activity of autoantibodies direct-
ed at FcεRIα and/or FcεRI-IgE complex. 
Most published data refer to chronic autoim-
mune urticaria in adults. Recently, a few articles 
Figure 3. Severe urticaria in patient 6. The lesions 
would appear and wane in 1-2 hours. There was 
an associated autoimmune hypothyroidism and 
cerebral AV malformation. The parents refused 
IVIG therapy for fear of the possible encephalo-
pathic adverse events.
Figure 4. Very discrete circinate urticarial lesions in 
patient 10. The parents and the child were deeply 
disturbed by bouts of recurrences every 3-4 days. 
IVIG therapy induced short lived remission.
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have dealt with chronic autoimmune urticaria in 
children (11,17-19). However, there is still a lack 
of published data on the prevalence of different 
types of urticaria in children, and on diagnostic ef-
ficiency of various diagnostic procedures. CU is 
rare in childhood. About 2.1% to 6.7% of children 
have urticaria (all forms, i.e. acute, intermittent and 
chronic) (20), and a small proportion of these chil-
dren have chronic or recurrent urticaria. In the UK 
National Referral Centre for Urticaria, 5% of urti-
caria patients are children up to 16 years with CU 
(1). In approximately 20% of patients, infectious or 
physical stimuli, aeroallergens, drugs, food addi-
tives, coloring agents and preservatives could be 
considered as the causative and/or triggering fac-
tors (21). Triggering factors in some of our patients 
were preservatives, dyes, insect sting, vaccine 
and drugs, but in the majority the trigger could not 
be identified. None of our patients had a positive 
family history of autoimmune diseases. Only one 
patient in our series had another autoimmune dis-
ease. A study by Brunetti et al. also suggests that 
the relative paucity of associated autoimmune dis-
ease is attributive to the pediatric age, as the like-
lihood of having autoimmune diseases increases 
with age (11). 
Standard laboratory analyses (complete blood 
count, urine analysis, chemistry analyses, comple-
ment components) and skin tests are usually non-
informative for the evaluation of CU. Increased 
total and specific IgE may be found more often in 
CU patients and also in those with an autoimmune 
disorder. 
CU is characterized by increased numbers of 
mastocytes in the dermis, which is the basis for 
occasional indication for biopsy or serum tryptase 
determination. Increased tryptase concentration is 
due to mastocyte activation. There is a reason to 
believe that patients with CU and increased serum 
tryptase suffer from a more severe clinical disease 
(22). The concentration of alpha-protryptase in se-
rum is used in the differential diagnosis of masto-
cytosis (22). 
The positive finding of autoantibodies directed 
against FcεRIα and/or the FcεRI-IgE complex is in-
dicative of a more severe clinical disease (23,24). 
According to Dayenas et al. (25), degranulation of 
basophil leukocytes can be induced by very low 
concentration of anti-IgE antibody in the assay 
(2.2x10-16/18 M). In vitro HR-urticaria test may de-
pend on complement (26). As an additional argu-
ment for autoimmunity, other autoantibodies may 
be present. The association of thyroid autoimmu-
nity with chronic urticaria has been reported in 
both adults (prevalence 14% to 33%) and children 
(prevalence 4.3%) (18). ANA and ANCA (antineu-
trophil antibodies) are only rarely positive (27). Ac-
cording to the results of Brunetti et al., the concor-
dance between ASST and HR-urticaria test (either 
positive or negative) was 83% (11).  Sulfidoleu-
kotriene release and the expression of CD63 acti-
vation marker on basophil leukocytes may add to 
the diagnostic certainty and also to the follow up 
under therapy (28). 
Anti-FcεRIα autoantibodies occur not only in 
patients with CU (38%) but can also be found in 
serum of patients suffering from other skin or sys-
temic autoimmune diseases such as pemphigus 
vulgaris (PV; 39%), dermatomyositis (DM; 36%), 
bullous pemphigoid (BP; 13%) and systemic lupus 
erythematosus (SLE; 20%) (29). While ASST and 
HR-urticaria test detect biologically relevant mast 
cell or basophil granulocyte-activating factors, 
ELISA, Western blotting and immunoprecipitation 
can be used for identification of specific autoanti-
bodies (29). However, although autoantibody titers 
in patients with PV, DM, BP and SLE were similar 
to those in CU patients, only CU serum samples 
displayed histamine-releasing activity. In addition, 
autoantibodies in CU patients belong mainly to 
complement-fixing IgG1 and IgG3 subclasses. In 
PV, DM and BP, they belong predominantly to IgG2 
and IgG4 subclasses. Anti-FcεRIα autoantibodies 
were not found in healthy individuals or in patients 
with atopic dermatitis or psoriatic patients (29). 
Since C5a receptor blockade on basophil granulo-
cytes as well as decomplementation reduced the 
histamine-releasing capacity of most anti-FcεRIα-
reactive CU serum specimens, complement sys-
tem is considered to be an augmentative and criti-
cal pathogenic factor in autoimmune-mediated CU 
(29). 
The proof of the autoimmune mechanism in 
CIU offers a theoretical possibility of immunomod-
ulatory or immunosuppressive treatment (30). The 
results of high-dose intravenous immunoglobulin 
or plasmapheresis have so far been anecdotal. 
Two of our patients entered long-lasting remission 
after IVIG therapy. Beforehand, the established 
treatment options should be exhausted, i.e. con-
sistent antihistamine therapy and low salicylate-
low preservative diet. If these measures fail over 
a period of 3-6 weeks, immunomodulatory and im-
munosuppressive treatment options may be con-
sidered, including high dose IVIG, corticosteroids, 
cyclosporine A and plasmapheresis (12).
Dodig and Richter       Acta Dermatovenerol Croat
Chronic autoimmune urticaria in children    2008;16(2):65-71
70 ACTA DERMATOVENEROLOGICA CROATICA
References
1.   Greaves MW. Chronic urticaria in childhood. 
Allergy 2000:55:309-20.
2.   Joint Task Force on Practice Parameters. The 
diagnosis and management of urticaria: a prac-
tice parameter part I: acute urticaria/angioede-
ma part II: chronic urticaria/angioedema. Ann 
Allergy Asthma Immunol 2000;85:521-44. 
3.   Shikiar R, Harding G, Leahy M, Lennox RD. 
Minimal Important Difference (MID) of the 
Dermatology Life Quality Index (DLQI): Re-
sults from patients with chronic idiopathic ur-
ticaria. Health and Quality of Life Outcomes 
2005;3:36-40.
4.   Benoist C, Mathis D. Mast cells in autoimmune 
disease. Nature 2002;420:875-8.
5.   Sabroe RA, Seed PT, Fraccis DM, Barr RM, 
Black AK, Greaves MW. Chronic idiopathic 
urticaria: comparison of the clinical featu-
res of patients with and without anti-FcεRI or 
anti-IgE autoantibodies. J Am Acad Dermatol 
1999;40:443-50. 
6.   Platzer MH, Grattan CEH, Poulsen LK, Skov 
PS. Validation of basophil histamine release 
against the autologous serum skin test and 
outcome of serum-induced basophil histamine 
release studies in a large population of chronic 
urticaria patients. Allergy 2005;60:1152-6.  
7.   Boguniewicz M. Chronic urticaria in children. 
Allergy Asthma Proc 2005;26:13-7.  
8.   Asero R, Lorini M, Chong SU, Zuberbier T, Te-
deschi A. Assessment of histamine-releasing 
activity of sera from patients with chronic ur-
ticaria showing positive autologous skin test 
on human basophils and mast cells. Clin Exp 
Allergy 2004;34:1111-4.
9.   Wedi B, Novacovic V, Koerner M, Kapp A. 
Chronic urticaria serum induces histamine 
release, leukotriene production, and basophil 
CD63 surface expression – inhibitory effects 
of anti-inflammatory drugs. J Allergy Clin Im-
munol 2000;105:552-60.
10. Vonakis BM, Saini SS. Basophils and mast 
cells in chronic idiopathic urticaria. Curr Al-
lergy Asthma Rep 2005;5:270-6.
11. Brunetti L, Francavilla R, Miniello VL, Platzer 
MH, Rizzi D, Lospalluti ML, et al. High pre-
valence of autoimmune urticaria in children 
with chronic urticaria. J Allergy Clin Immunol 
2004;114:922-7.
12. Zuberbier T, Bindslev-Jensen C, Canonica 
W, Grattan CE, Greaves MW, Henz BM, et 
al. EAACI/GA2LEN/EDF guideline: definition, 
classification and diagnosis of urticaria. Al-
lergy 2006;61:316-20.
13. Voller A, Bartlerr A, Bidwell D. Immunoas-
says for ‘80s. Baltimore: University Press, 
1981:508-12.
14. Paganelli R, Paganelli R, Ansotegui IJ, Sastre 
J, Lange CF, Roovers MH, et al. Specific IgE 
antibodies in the diagnosis of atopic disease. 
Clinical evaluation of a new in vitro test sys-
tem, UniCAPTM, in six European allergy clinics. 
Allergy 1998;53:763-8.
15. Stahl Skov P, Mosbech H, Norn S. Sensitive 
glass microfibre based histamine analysis for 
allergy testing in washed blood cells. Results 
compared with conventional leukocyte hista-
mine release assay. Allergy 1985;40:213-8.
16. Dodig S, Richter D, Benko B, Živčić J, Raos 
M, Nogalo B, et al. Cut-off values for total se-
rum immunoglobulin E between non-atopic 
and atopic children in north-west Croatia. Clin 
Chem Lab Med 2006;44:639-47. 
17. Dalal I. Chronic urticaria in children: expan-
ding the “autoimmune kaleidoscope”. Pedia-
trics 2000;106:1139-41. 
18. Levy Y, Segal N, Weintrob N, Danon YN. Ch-
ronic urticaria: association with thyroid autoim-
munity. Arch Dis Child 2003;88:517-9.
19. Asero R, Lorini M, Tedeschi A. Chronic auto-
reactive urticaria at six years of age. J Investig 
Allergol Clin Immunol 2004;1:343-5. 
20. Henz BM, Zuberbier T, Grabre J, Monroe G. 
Urticaria: clinical diagnosis and therapeutic 
aspects. In: Henz BM, Zuberbier T, editors. 
Urticaria. Berlin: Springer; 1998: pp. 1-210.
21. Greaves MW. Review article Series V: The 
skin as target for IgE-mediated allergic reac-
tions. Chronic urticaria in childhood. Allergy 
2000;55:309-20.
22. Hidvegi B, Nagy E, Szabo T, Temesvari E, 
Marschalko M, Karpati S, et al. Correlation 
between T-cell and mast cell activity in patients 
with chronic urticaria. Int Arch Allergy Immunol 
2003;132:177-82. 
23. Sabroe RA, Seed PT, Francis DM, Barr 
RM, Black AK, Greaves MW. Chronic idiopa-
thic urticaria: comparison of the clinical fea-
tures of patients with and without anti-Fcep-
Dodig and Richter       Acta Dermatovenerol Croat
Chronic autoimmune urticaria in children    2008;16(2):65-71
71ACTA DERMATOVENEROLOGICA CROATICA
silonRI or anti-IgE autoantibodies. J Am Acad 
Dermatol 1999;40:443-50.  
24. Hidvegi B, Sabroe RA, Fiebiger E, Francis 
DM, Maurer D, Seed PT, et al. Classification of 
anti-FcepsilonRI and anti-IgE autoantibodies 
in chronic idiopathic urticaria and correlation 
with disease severity. J Allergy Clin Immunol. 
2002;110:492-9.
25. Davenas E, Beauvais F, Amara J, Oberbaum 
M, Robinzon B, Miadonna A, et al. Human 
basophil degranulation triggered by very dilute 
antiserum against IgE. Nature 1988;333:816-
8.
26. Asero R, Tedeschi A, Lorini M, Salimbeni R, 
Zanoletti T, Miadonna A. Chronic urticaria: no-
vel clinical and serological aspects. Clin Exp 
Allergy 2001;31:1105-10.
27. Rumbyrt JS, Katz JL, Schocket AL. Resolu-
tion of chronic urticaria in patients with thy-
roid autoimmunity. J Allergy Clin Immunol 
1995;96:901-5.
28. Wedi B, Ebo DG, Sainte-Laudy J, Bridts CH, 
Mertens CH, Hadendorens MM, et al. Flow-as-
sisted allergy diagnosis: current applications 
and future perspectives. Allergy 2006;61:1028-
39.
29. Fiebiger E, Hammerschmnid F, Stingl G, Mau-
rer D. Anti-FcεRIα-autoantibodies in autoim-
mune-mediated disorders. Identification of a 
structure-function relationship. J Clin Invest 
1998;101:243-51.
30. Kozel MM, Sabroe RA. Chronic urticaria: ae-
tiology, management and current and future 
treatment options. Drugs 2004;64:2515-36.
Dodig and Richter       Acta Dermatovenerol Croat
Chronic autoimmune urticaria in children    2008;16(2):65-71
Joyful play in the sun and the water please body and soul. Elida cream; year 1934.
(from the collection of Mr. Zlatko Puntijar)
